Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Ryden

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
Journal of the American College of Cardiology|February 25, 2003
Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring systemPhilip B Adamson, Anthony Magalski, Frieder Braunschweig, et al.
Circulation|September 28, 2011
Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET)Giuseppe Mancia, Helmut Schumacher, Josep Redon, et al.
Global Heart|August 28, 2019
A Roadmap on the Prevention of Cardiovascular Disease Among People Living With DiabetesSharon Mitchell, Belma Malanda, Albertino Damasceno, et al.
Diabetes Care|April 9, 2013
Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE)Eva M Lonn, Jackie Bosch, Rafael Diaz, et al.
Diabetes Care|March 10, 2023
Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc AnalysisHertzel C Gerstein, Shun-Fu Lee, Guillaume Paré, et al.
Diabetes Research and Clinical Practice|May 27, 2021
Towards living guidelines on cardiorenal outcomes in diabetes: A pilot project of the Taskforce of the Guideline Workshop 2020Nikolaus Marx, Lars Ryden, Frank Brosius, et al.
American Heart Journal|June 23, 2014
Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trialRury R Holman, Mary A Bethel, Juliana C N Chan, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|August 24, 2022
The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trialAndre Lamy, John Eikelboom, Wesley Tong, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|December 28, 2023
The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US PerspectiveAndre Lamy, John Eikelboom, Wesley Tong, et al.
Diabetes & Vascular Disease Research|October 21, 2017
Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromesStefano Savonitto, Nuccia Morici, Anna Nozza, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Journal of the American College of Cardiology|February 25, 2003
Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring systemPhilip B Adamson, Anthony Magalski, Frieder Braunschweig, et al.
Circulation|September 28, 2011
Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET)Giuseppe Mancia, Helmut Schumacher, Josep Redon, et al.
Global Heart|August 28, 2019
A Roadmap on the Prevention of Cardiovascular Disease Among People Living With DiabetesSharon Mitchell, Belma Malanda, Albertino Damasceno, et al.
Diabetes Care|April 9, 2013
Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE)Eva M Lonn, Jackie Bosch, Rafael Diaz, et al.
Diabetes Care|March 10, 2023
Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc AnalysisHertzel C Gerstein, Shun-Fu Lee, Guillaume Paré, et al.
Diabetes Research and Clinical Practice|May 27, 2021
Towards living guidelines on cardiorenal outcomes in diabetes: A pilot project of the Taskforce of the Guideline Workshop 2020Nikolaus Marx, Lars Ryden, Frank Brosius, et al.
American Heart Journal|June 23, 2014
Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trialRury R Holman, Mary A Bethel, Juliana C N Chan, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|August 24, 2022
The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trialAndre Lamy, John Eikelboom, Wesley Tong, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|December 28, 2023
The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US PerspectiveAndre Lamy, John Eikelboom, Wesley Tong, et al.
Diabetes & Vascular Disease Research|October 21, 2017
Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromesStefano Savonitto, Nuccia Morici, Anna Nozza, et al.
Pageof 5